Equity Incentive Plan - Narrative (Details) - 2020 Plan $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Mar. 31, 2021 trading_day $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares reserved for issuance, annual increase criteria, total number of common shares outstanding, percent (lesser of)		5.00%
Shares available for grant (in shares) \| shares		812,032
Options exercised, intrinsic value		$ 863
Options outstanding, intrinsic value		400
Options exercisable, intrinsic value		$ 400
Chief Executive Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost, recognition period		1 month 6 days
Granted (in shares) \| shares	727,922
Exercise price (in dollars per share) \| $ / shares	$ 3.00
Options, minimum number of trading days after becoming listed, vesting criteria numerator \| trading_day	20
Options, minimum number of trading days after becoming listed, vesting criteria denominator \| trading_day	30
Unamortized share-based compensation expense		$ 6
Stock options and stock appreciation rights
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Contractual life (up to)		10 years
Unrecognized compensation cost		$ 2,500
Unrecognized compensation cost, recognition period		2 years 2 months 12 days
Stock options and stock appreciation rights \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period (not greater than)		4 years
Stock Appreciation Rights (SARs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average grant date fair value, non-options (in dollars per share) \| $ / shares		$ 2.33	$ 1.13
Granted (in dollars per share) \| $ / shares		$ 2.33	$ 1.13
Restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost, recognition period		3 years 7 months 6 days
Intrinsic value, outstanding		$ 1,800
Non-option, unrecognized compensation cost		$ 7,900

Augmedix, Inc. 10-Q